Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
03/2003
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018026A1 Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003017988A1 Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups
03/06/2003WO2003017979A1 Method for the production of inhalation powders
03/06/2003WO2003017971A1 Drug delivery system
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085447A3 Microprojection array having a beneficial agent containing coating
03/06/2003WO2002085376A3 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
03/06/2003WO2002022132A8 Novel topical oestroprogestational compositions with systemic effect
03/06/2003WO2002003984A3 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003US20030045829 Therapeutic agent delivery tampon
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045557 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045454 Sustained release formulation
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003CA2458866A1 Compositions and methods of treating diabetes
03/06/2003CA2458445A1 Extracellular messengers
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457979A1 A delivery system
03/06/2003CA2449515A1 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1287122A2 Human pancreatic islet glucose-6-phosphatase
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287031A2 Polynucleotides encoding for polymorphic isoforms of the pthrp protein, the encoded proteins and their therapeutic applications thereof
03/05/2003EP1287017A1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
03/05/2003EP1286989A2 Prodrug of an ice inhibitor
03/05/2003EP1286966A1 4-aminopiperidine derivatives and their use as medicine
03/05/2003EP1286962A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
03/05/2003EP1286957A1 Diphenylmethane derivatives
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286693A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
03/05/2003EP1286673A2 Ligands of integrin receptors
03/05/2003EP1286666A2 Starter kit for low dose oral contraceptives
03/05/2003EP1286659A2 Macromolecular drug complexes and compositions containing the same
03/05/2003EP1140972B1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
03/05/2003EP0892791B1 N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
03/05/2003EP0853610B1 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
03/05/2003EP0835262B1 Method for the treatment of corticosteroid induced osteopenia
03/05/2003EP0832069B1 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
03/05/2003EP0728143B1 Oncoprotein protein kinase
03/05/2003CN1400904A Selective estrogen receptor modulators in combination with estrogens
03/05/2003CN1400897A Transdermal delivery LASOFOXIFENE
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528485 Human growth hormone releasing factor-PEG conjugates; PEG unit is covalently bound to the amino group of Lys21 of SEQ ID NO:1; the hGRF-PEG conjugate does not contain a triazine group
03/03/2003WO2002019971A1 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
02/2003
02/27/2003WO2003016335A2 Irreversible cysteine protease inhibitors of legumain
02/27/2003WO2003016291A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
02/27/2003WO2003015872A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders
02/27/2003WO2003015822A1 5-cnac as oral delivery agent for parathyroid hormone fragments
02/27/2003WO2003015820A1 GnRH AGONIST COMBINATION DRUGS
02/27/2003WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003WO2003015793A1 Delayed and sustained drug release
02/27/2003WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
02/27/2003WO2003015761A1 Selective estrogen receptor modulators
02/27/2003WO2003015751A1 Pharmaceutical composition for nasal delivery of estradiol and norethisterone
02/27/2003WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
02/27/2003WO2003015693A2 Screening and therapeutic methods for promoting wakefulness and sleep
02/27/2003WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes
02/27/2003WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
02/27/2003WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid
02/27/2003WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
02/27/2003WO2002043695A3 Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol
02/27/2003WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
02/27/2003WO2002017911A1 Parathyroid hormone production inhibitors containing vitamin d3 derivatives
02/27/2003US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease
02/27/2003US20030040535 Tetrazole compounds as thyroid receptor ligands
02/27/2003US20030040533 For use as hypoglycaemic and hypolipidaemic agents
02/27/2003US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity
02/27/2003US20030040510 Selective estrogen receptor modulators in combination with estrogens
02/27/2003US20030040509 Methods and compositions for treating diseases associated with excesses in ACE
02/27/2003US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation
02/27/2003US20030040483 Compounds with growth hormone releasing properties
02/27/2003US20030040482 For therapy of precocious puberty, prostate cancer, ovarian cancer, benign prostatic hypertrophy, endometriosis, uterine fibroids, breast cancer, premenstrual syndrome, polycystic ovary syndrome, disease caused by excesses of gonadal hormones
02/27/2003US20030040044 Anti-dual integrin antibodies, compositions, methods and uses
02/27/2003US20030039701 Mixture containing animal extract from deer antlers
02/27/2003US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption
02/27/2003CA2493349A1 Delayed and sustained drug release
02/27/2003CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
02/27/2003CA2459434A1 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders
02/27/2003CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003CA2456150A1 Selective estrogen receptor modulators
02/27/2003CA2454671A1 Pharmaceutical composition for nasal delivery of estradiol and norethisterone
02/27/2003CA2420759A1 Parathyroid hormone production inhibitors containing vitamin d3 derivatives
02/26/2003EP1285927A2 Use of glucocorticoid antagonists for the prevention and treatment of diseases of the male reproductive system
02/26/2003EP1285665A1 Liquid gonadotropin containing formulations
02/26/2003EP1285664A2 Methods of increasing lean tissue mass using OB protein compositions
1 ... 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 ... 290